Group One Trading
GALT icon

Group One Trading’s Galectin Therapeutics GALT Stock Holding History

Group One Trading’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8K Sell
6,000
-470,200
-99% -$1.22M ﹤0.01% 5795
2026
Q1 		$1.33M Sell
476,200
-160,900
-25% -$489K ﹤0.01% 2448
2025
Q4 		$2.65M Buy
637,100
+494,400
+346% +$2.6M ﹤0.01% 2029
2025
Q3 		$604K Buy
142,700
+124,500
+684% +$468K ﹤0.01% 3499
2025
Q2 		$38.4K Buy
18,200
+9,900
+119% +$14.8K ﹤0.01% 5792
2025
Q1 		$10.1K Sell
8,300
-673,400
-99% -$945K ﹤0.01% 6255
2024
Q4 		$879K Buy
681,700
+515,300
+310% +$1.23M ﹤0.01% 2688
2024
Q3 		$458K Buy
166,400
+162,400
+4,060% +$399K ﹤0.01% 2917
2024
Q2 		$9.04K Buy
4,000
+3,800
+1,900% +$11.5K ﹤0.01% 5682
2024
Q1 		$478 Sell
200
-8,200
-98% -$15.5K ﹤0.01% 6745
2023
Q4 		$13.9K Sell
8,400
-900
-10% -$1.75K ﹤0.01% 5988
2023
Q3 		$17.9K Buy
9,300
+1,400
+18% +$2.3K ﹤0.01% 5966
2023
Q2 		$11.4K Sell
7,900
-300
-4% -$509 ﹤0.01% 6327
2023
Q1 		$17.2K Buy
8,200
+6,300
+332% +$10.2K ﹤0.01% 5607
2022
Q4 		$2.15K Sell
1,900
-6,700
-78% -$8.93K ﹤0.01% 6637
2022
Q3 		$14K Sell
8,600
-3,200
-27% -$5.98K ﹤0.01% 6290
2022
Q2 		$15K Sell
11,800
-26,400
-69% -$38K ﹤0.01% 6503
2022
Q1 		$62K Sell
38,200
-34,900
-48% -$67.5K ﹤0.01% 5933
2021
Q4 		$151K Sell
73,100
-196,200
-73% -$560K ﹤0.01% 5370
2021
Q3 		$1.04M Sell
269,300
-69,000
-20% -$234K ﹤0.01% 3365
2021
Q2 		$1.08M Buy
338,300
+309,600
+1,079% +$1.1M ﹤0.01% 3320
2021
Q1 		$62K Buy
28,700
+17,700
+161% +$39.7K ﹤0.01% 6069
2020
Q4 		$25K Sell
11,000
-27,900
-72% -$73.2K ﹤0.01% 5393
2020
Q3 		$104K Sell
38,900
-5,600
-13% -$15.7K ﹤0.01% 4166
2020
Q2 		$136K Buy
44,500
+16,200
+57% +$40.8K ﹤0.01% 3673
2020
Q1 		$55K Sell
28,300
-9,200
-25% -$22.4K ﹤0.01% 3649
2019
Q4 		$107K Buy
37,500
+3,700
+11% +$12.9K ﹤0.01% 3592
2019
Q3 		$124K Buy
33,800
+16,100
+91% +$58.2K ﹤0.01% 3414
2019
Q2 		$73K Sell
17,700
-78,000
-82% -$338K ﹤0.01% 3566
2019
Q1 		$489K Buy
95,700
+39,700
+71% +$191K 0.01% 1961
2018
Q4 		$192K Sell
56,000
-22,200
-28% -$106K ﹤0.01% 2722
2018
Q3 		$470K Buy
78,200
+44,900
+135% +$247K ﹤0.01% 2344
2018
Q2 		$212K Sell
33,300
-81,400
-71% -$396K ﹤0.01% 3004
2018
Q1 		$544K Sell
114,700
-189,700
-62% -$884K 0.01% 1998
2017
Q4 		$1.02M Buy
304,400
+162,200
+114% +$410K 0.01% 1686
2017
Q3 		$301K Sell
142,200
-42,200
-23% -$83.6K ﹤0.01% 2468
2017
Q2 		$454K Sell
184,400
-62,700
-25% -$167K ﹤0.01% 2038
2017
Q1 		$568K Buy
+247,100
New +$372K 0.01% 1767

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Group One Trading's GALT Position: Q2 2026 in Review

Group One Trading opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 13,753 shares worth $63.8K. The stake represents ﹤0.01% of the portfolio and ranks #5202 among its holdings. This is a return to the name: Group One Trading previously reported a position in GALT as recently as Q3 2025.

Group One Trading first reported a position in GALT in Q3 2017 and has held it in 15 quarters since. The position peaked at $690K in Q2 2018. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Group One Trading held 13,753 shares of Galectin Therapeutics worth $63.8K as of Q2 2026.
  • Galectin Therapeutics was a new Group One Trading position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5202 holding.
  • Group One Trading first reported a position in Galectin Therapeutics in Q3 2017 and has held it in 15 quarters since.
  • Group One Trading's Galectin Therapeutics position peaked at $690K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.